CLNN Clene Inc

Clene to Present at Upcoming October Conferences

Clene to Present at Upcoming October Conferences

SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in October.

2024 Maxim Healthcare Virtual Summit

Date: October 15-17, 2024

Location: Virtual

Presentation: October 15, 2024, at 2:30 p.m. E.T.

Format: Fireside Presentation and 1x1 meetings

Attendance: Sign up to become an

The ThinkEquity Conference 2024

Dates: October 30, 2024

Location: New York, New York, Mandarin Oriental Hotel

Presentation: October 30, 2024, at 3:30 p.m. E.T.

Format: Presentation and 1x1 meetings

Webcast Link:

About Clene

Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit or follow us on and .

Contacts:

Media Contact

Ignacio Guerrero-Ros, Ph.D., or David Schull

Russo Partners, LLC





(858) 717-2310		Investor Contact

Kevin Gardner

LifeSci Advisors



617-283-2856


EN
09/10/2024

Underlying

CLNNClene Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Clene Inc

 PRESS RELEASE
Free
CLNN CLENE INC

Clene to Present at the Emerging Growth Conference

Clene to Present at the Emerging Growth Conference SALT LAKE CITY, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: January 21, 2026Time of Pre...

January 16, 2026 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential...

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are significantly associated with lower mortality risk, supporting NfL reduction as a candidate surrogate endpoint for accelerated approvalNew exploratory findings demonstrate that in responders with IGFBP7 biomarker decline, CNM-Au8 30mg was strongly associated with 78% reduced mortality...

January 12, 2026 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene Announces Registered Direct Offering of Over $28 Million

Clene Announces Registered Direct Offering of Over $28 Million Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo CapitalInitial financing tranche of over $6 million, which we expect will provide cash runway into the third quarter of 2026 enabling funding through potential NDA acceptance decision by the FDA, with two additional financing tranches totaling over $22 million contingent on NDA acceptance and NDA approval by the FDACompletion of this financing through its three tra...

January 9, 2026 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene to Present at the Emerging Growth Conference

Clene to Present at the Emerging Growth Conference SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: December 10, 2025Time of Pr...

December 9, 2025 1 EN
 PRESS RELEASE
Free
CLNN CLENE INC

Clene Announces Statistically Significant ALS Biomarker Results Suppor...

Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8® FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8’s potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today...

December 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch